RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Clinical Trial ID NCT01193881

PubWeight™ 8.48‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01193881

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol 2015 2.02
2 The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. Cancer Manag Res 2013 1.22
3 Molecular pathways and therapeutic targets in lung cancer. Oncotarget 2014 1.16
4 A phase II study of RO4929097 in metastatic colorectal cancer. Eur J Cancer 2012 1.05
5 Wound healing and cancer stem cells: inflammation as a driver of treatment resistance in breast cancer. Cancer Growth Metastasis 2015 0.90
6 Notch signaling in serous ovarian cancer. J Ovarian Res 2014 0.87
7 Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer. Onco Targets Ther 2013 0.85
8 Nrf2 and Notch Signaling in Lung Cancer: Near the Crossroad. Oxid Med Cell Longev 2016 0.78
Next 100